Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0466 in Advanced Non-Hodgkin Lymphoma
NCT05205161Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Nanoparticles, Small Molecules, Peptide-Drug Conjugates
- Countries
- 7
01
Overview
Phase 1, open-label trial of AZD0466 in non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and 2 more (8 arms), sponsored by AstraZeneca. Primary endpoints: Number of Participants With Adverse Events (AE) and Number of Participants With Dose Limiting Toxicity (DLT). Started Jul 2022; status: terminated.
02
Drugs
AZD0466
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05205161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205161.